Alignment Healthcare, Inc. (NASDAQ:ALHC - Get Free Report) insider Hakan Kardes sold 35,000 shares of the company's stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $12.80, for a total transaction of $448,000.00. Following the completion of the transaction, the insider now owns 320,444 shares of the company's stock, valued at approximately $4,101,683.20. The trade was a 9.85 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Hakan Kardes also recently made the following trade(s):
- On Monday, November 4th, Hakan Kardes sold 20,500 shares of Alignment Healthcare stock. The stock was sold at an average price of $13.06, for a total transaction of $267,730.00.
- On Friday, November 1st, Hakan Kardes sold 4,500 shares of Alignment Healthcare stock. The shares were sold at an average price of $12.98, for a total value of $58,410.00.
- On Thursday, September 12th, Hakan Kardes sold 25,000 shares of Alignment Healthcare stock. The stock was sold at an average price of $11.48, for a total value of $287,000.00.
Alignment Healthcare Stock Down 1.7 %
Shares of NASDAQ:ALHC opened at $12.61 on Friday. The company has a market cap of $2.42 billion, a price-to-earnings ratio of -16.38 and a beta of 1.45. Alignment Healthcare, Inc. has a 12 month low of $4.46 and a 12 month high of $14.25. The company has a current ratio of 1.60, a quick ratio of 1.60 and a debt-to-equity ratio of 1.82. The company has a 50-day moving average price of $11.81 and a 200 day moving average price of $9.75.
The latest trend in real estate
From Pacaso | Ad
These vacation homes are often expensive to maintain and vacant 90% of the year. But thanks to co-ownership, they’re being transformed into fully utilized assets. And there’s one company that’s leading the charge – already welcoming over 1,500 happy homeowners into their co-ownership family, earning $100M in gross profits along the way.
Now, for the first time, this innovative company is opening its doors to public investors. Want to learn more about co-ownership and its potential? Check them out – but be aware: their share price is set to change December 5, so you don’t have long to maximize your stake.
Don’t miss your chance to maximize your stake in this co-ownership revolution.
Alignment Healthcare (NASDAQ:ALHC - Get Free Report) last posted its quarterly earnings data on Tuesday, October 29th. The company reported ($0.14) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.14). The business had revenue of $692.43 million during the quarter, compared to analyst estimates of $662.11 million. Alignment Healthcare had a negative return on equity of 108.69% and a negative net margin of 5.84%. The company's revenue for the quarter was up 51.6% on a year-over-year basis. During the same period last year, the company earned ($0.19) EPS. As a group, equities research analysts predict that Alignment Healthcare, Inc. will post -0.69 earnings per share for the current year.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of the company. Virtu Financial LLC purchased a new position in shares of Alignment Healthcare during the 1st quarter worth about $57,000. nVerses Capital LLC purchased a new position in shares of Alignment Healthcare during the third quarter valued at approximately $95,000. Principal Financial Group Inc. boosted its position in shares of Alignment Healthcare by 18.1% during the second quarter. Principal Financial Group Inc. now owns 13,521 shares of the company's stock valued at $106,000 after buying an additional 2,077 shares during the period. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Alignment Healthcare during the third quarter valued at approximately $131,000. Finally, Creative Planning lifted its stake in shares of Alignment Healthcare by 20.0% during the 3rd quarter. Creative Planning now owns 12,442 shares of the company's stock worth $147,000 after acquiring an additional 2,072 shares during the last quarter. Institutional investors own 86.19% of the company's stock.
Analyst Ratings Changes
A number of research analysts recently commented on ALHC shares. Robert W. Baird boosted their price target on Alignment Healthcare from $10.00 to $11.00 and gave the stock an "outperform" rating in a report on Wednesday, August 14th. TD Cowen upped their target price on shares of Alignment Healthcare from $8.00 to $10.00 and gave the stock a "buy" rating in a research report on Tuesday, August 6th. Piper Sandler reiterated an "overweight" rating and issued a $10.00 price target (up from $8.00) on shares of Alignment Healthcare in a report on Tuesday, August 6th. UBS Group increased their price objective on shares of Alignment Healthcare from $9.00 to $12.00 and gave the company a "neutral" rating in a report on Wednesday, October 30th. Finally, Barclays lifted their target price on Alignment Healthcare from $7.00 to $8.00 and gave the stock an "underweight" rating in a report on Wednesday, October 30th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Alignment Healthcare presently has an average rating of "Moderate Buy" and a consensus price target of $10.33.
Get Our Latest Stock Report on ALHC
About Alignment Healthcare
(
Get Free Report)
Alignment Healthcare, Inc, a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
